Votubia® (everolimus) tablets* is approved for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery. The evidence is based on analysis of change in sum of angiomyolipoma volume. Votubia is also approved for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.
Votubia targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.
For more information on other areas of research, please visit EVEROLIMUS in the research section.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative. Everolimus is not approved for this indication in all countries.
*Known as Votubia (everolimus) tablets for this patient population in the EU and Switzerland. Approved in the US for this patient population under the trade name Afinitor (everolimus) tablets.
